Wall Street analyst estimates for None (BLRX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-23 | $-0.39 | ||
| 2026-08-31 | $-0.77 | $-0.15 | -413.3% |
| 2026-05-27 | $-0.58 | $-1.04 | +44.2% |
| 2026-03-23 | $-0.34 | $-0.50 | +32.0% |
| 2025-11-24 | $-0.22 | $-0.41 | +46.3% |
| 2025-08-14 | $-1.00 | $-0.35 | -185.7% |
| 2025-05-27 | $1.39 | $-0.84 | +265.5% |
| 2025-03-31 | $-1.60 | $-0.81 | -98.2% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $4.8M | $28.9M | $1.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $3.7M | $9.3M | $758973 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.1M | $19.7M | $430387 |
| Research & Development | $11.2M | $19.5M | $19.8M | $23.4M | $18.2M | $19.5M | $17.6M | $12.5M | $9.1M | $7.7M |
| Selling, General & Admin | $5.3M | $5.7M | $5.8M | $4.6M | $4.7M | $5.3M | $11.5M | $31.2M | $28.5M | $3.1M |
| Operating Expenses | $16.5M | $25.2M | $25.6M | $28.1M | $22.9M | $24.8M | $29.2M | $50.8M | $40.1M | $10.8M |
| Operating Income | -$16.5M | -$25.2M | -$25.6M | -$28.1M | -$22.9M | -$24.8M | -$29.2M | -$49.7M | -$20.4M | -$10.4M |
| EBITDA | -$15.3M | -$24.8M | -$22.0M | -$22.7M | -$27.6M | -$25.4M | -$22.1M | -$57.1M | $3.9M | -$224770 |
| Interest Expense | $14000 | $21000 | $21000 | $1.8M | $1.5M | $984000 | $2.2M | $2.2M | $9.2M | $1.3M |
| Pre-tax Income | -$15.8M | -$24.4M | -$23.0M | -$25.4M | -$30.0M | -$27.1M | -$25.0M | -$60.6M | -$9.2M | -$2.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$15.8M | -$24.4M | -$23.0M | -$25.4M | -$30.0M | -$27.1M | -$25.0M | -$60.6M | -$9.2M | -$1.2M |
| EPS | $-168.00 | $-162.00 | $-126.00 | $-108.00 | $-72.00 | $-24.48 | $-19.32 | $-37.74 | $-4.62 | $-0.29 |
| EPS (Diluted) | $-168.00 | $-162.00 | $-126.00 | $-108.00 | $-72.00 | $-24.48 | $-19.32 | $-37.74 | $-4.62 | $-0.29 |
| Shares Outstanding (Diluted) | $93574 | $149951 | $180992 | $244011 | $421407 | $1.1M | $1.3M | $1.6M | $2.0M | $4.1M |
Price
| Price | $2.48 |
| Market Cap | $11M |
Related companies: ADAP · ADTX · AIMD · ANL · APLM · GOVX · ICU
More sections of BLRX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks